MULTIVARIATE-ANALYSIS OF PROGNOSTIC FACTORS IN PATIENTS WITH NON HIV-RELATED PRIMARY CEREBRAL LYMPHOMA - A PROPOSAL FOR A PROGNOSTIC SCORING

被引:36
作者
BLAY, JY
LASSET, C
CARRIE, C
CHAUVIN, F
COIFFIER, B
GISSELBRECHT, C
CLAVEL, M
REBATTU, P
BRUNATMENTIGNY, M
PHILIP, T
BIRON, P
机构
[1] CTR LEON BERARD,DEPT RADIOTHERAPIE,F-69008 LYON,FRANCE
[2] CTR LEON BERARD,DEPT MED,F-69008 LYON,FRANCE
[3] CTR HOSP LYON SUD,SERV HEMATOL,F-69310 PIERRE BENITE,FRANCE
[4] HOP ST LOUIS,SERV HEMATOL,F-75010 PARIS,FRANCE
关键词
D O I
10.1038/bjc.1993.209
中图分类号
R73 [肿瘤学];
学科分类号
100214 ;
摘要
Between 1982 and 1991, 41 patients were treated for non HIV related primary cerebral lymphoma (PCL) in our institute. The purpose of this study was to perform a multivariate analysis of prognostic factors for survival in these patients. The presence of a CSF protein level over 0.6 g l-1 at diagnosis was found to be the most significant unfavourable prognostic factor in univariate analysis and had not previously been reported. Among the five significant prognostic factors at diagnosis, (age over 60 years, performance status - ECOG scale - over 2, memory dysfunction, non hemispheric tumour site, CSF protein level over 0.6 g l-1 at the diagnosis), three independent factors were identified in multivariate analysis: (1) CSF protein level (P = 0.007; RR = 4.7); (2) PS > 2 (P = 0.04, RR = 2.65); (3) age over 60 (P = 0.08; RR = 2.43). Using the regression coefficient of these three parameters, we determined a prognostic index which allowed us to distinguish three risk groups whose theoretical median survival is 4, 20 and 54, months respectively in patients with non HIV related PCL. These results indicate that PCL is an heterogenous disease in terms of the prognostic in which three subgroups with discriminant survival can be identified.
引用
收藏
页码:1136 / 1141
页数:6
相关论文
共 40 条
[1]   RADIATION-THERAPY IN THE MANAGEMENT OF PRIMARY MALIGNANT-LYMPHOMA OF THE BRAIN [J].
BERRY, MP ;
SIMPSON, WJ .
INTERNATIONAL JOURNAL OF RADIATION ONCOLOGY BIOLOGY PHYSICS, 1981, 7 (01) :55-59
[2]   MANAGEMENT OF PRIMARY CEREBRAL LYMPHOMA WITH INITIAL CHEMOTHERAPY - PRELIMINARY-RESULTS AND COMPARISON WITH PATIENTS TREATED WITH RADIOTHERAPY ALONE [J].
BRADA, M ;
DEARNALEY, D ;
HORWICH, A ;
BLOOM, HJG .
INTERNATIONAL JOURNAL OF RADIATION ONCOLOGY BIOLOGY PHYSICS, 1990, 18 (04) :787-792
[3]   PROGNOSTIC INDEX FOR THYROID-CARCINOMA - STUDY OF THE EORTC-THYROID-CANCER-COOPERATIVE-GROUP [J].
BYAR, DP ;
GREEN, SB ;
DOR, P ;
WILLIAMS, ED ;
COLON, J ;
VANGILSE, HA ;
MAYER, M ;
SYLVESTER, RJ ;
VANGLABBEKE, M .
EUROPEAN JOURNAL OF CANCER, 1979, 15 (08) :1033-1041
[4]  
CANELLOS GP, 1987, SEMIN HEMATOL, V24, P2
[5]   LNH-84 REGIMEN - A MULTICENTER STUDY OF INTENSIVE CHEMOTHERAPY IN 737 PATIENTS WITH AGGRESSIVE MALIGNANT-LYMPHOMA [J].
COIFFIER, B ;
GISSELBRECHT, C ;
HERBRECHT, R ;
TILLY, H ;
BOSLY, A ;
BROUSSE, N .
JOURNAL OF CLINICAL ONCOLOGY, 1989, 7 (08) :1018-1026
[6]  
COX DR, 1972, J R STAT SOC B, V34, P187
[7]   PRIMARY CNS LYMPHOMA - COMBINED TREATMENT WITH CHEMOTHERAPY AND RADIOTHERAPY [J].
DEANGELIS, LM ;
YAHALOM, J ;
HEINEMANN, MH ;
CIRRINCIONE, C ;
THALER, HT ;
KROL, G .
NEUROLOGY, 1990, 40 (01) :80-86
[8]   COMBINED MODALITY THERAPY FOR PRIMARY CNS LYMPHOMA [J].
DEANGELIS, LM ;
YAHALOM, J ;
THALER, HT ;
KHER, U .
JOURNAL OF CLINICAL ONCOLOGY, 1992, 10 (04) :635-643
[9]  
EBY NL, 1988, CANCER, V62, P2461, DOI 10.1002/1097-0142(19881201)62:11<2461::AID-CNCR2820621135>3.0.CO
[10]  
2-M